Literature DB >> 9207375

Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy.

T Weber1, C Trebst, S Frye, P Cinque, L Vago, C J Sindic, W J Schulz-Schaeffer, H A Kretzschmar, W Enzensberger, G Hunsmann, W Lüke.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a subacute viral infection of oligodendrocytes by JC virus occurring almost exclusively in immunocompromised patients. By use of partially purified recombinant VP1 as antigen, the IgG response was analyzed by a quantitative ELISA of paired cerebrospinal fluid (CSF) and serum samples. An intrathecal immune response to VP1, defined as an antibody-specificity index of CSF to serum antibody titers > or =1.5, was found in 76% of PML patients (47/62) but in only 3.2% of controls (5/155) (P < .001). Intra-blood-brain barrier synthesis of VP1-specific IgG antibodies is 76% sensitive and 96.8% specific for the diagnosis of PML. Furthermore, the excellent correlation (r = .985) between the plasma cell count in brain tissue and the humoral intrathecal immune response to VP1 in PML patients suggests a role for B cells in this disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207375     DOI: 10.1086/514032

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  58 in total

1.  Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.

Authors:  C Goldmann; H Petry; S Frye; O Ast; S Ebitsch; K D Jentsch; F J Kaup; F Weber; C Trebst; T Nisslein; G Hunsmann; T Weber; W Lüke
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy.

Authors:  C T Yiannoutsos; A De Luca
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

3.  Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Authors:  J Kuhle; R Gosert; R Bühler; T Derfuss; R Sutter; O Yaldizli; E-W Radue; C Ryschkewitsch; E O Major; L Kappos; S Frank; H H Hirsch
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

Review 4.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

Review 5.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

6.  Progressive multifocal leukoencephalopathy in a patient with multiple myeloma.

Authors:  Masaru Akiyama; Toru Takahashi; Sinjo Nomura; Yoshimi Yamashita; Katsuhiro Hatao
Journal:  Int J Hematol       Date:  2010-05-28       Impact factor: 2.490

7.  Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy.

Authors:  Marco A Lima; Angela Marzocchetti; Patrick Autissier; Troy Tompkins; Yiping Chen; Jennifer Gordon; David B Clifford; Rajesh T Gandhi; Nagagopal Venna; Joseph R Berger; Igor J Koralnik
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

8.  Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient.

Authors:  F Bernal-Cano; J T Joseph; I J Koralnik
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

9.  Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals.

Authors:  R A Du Pasquier; J E Schmitz; J Jean-Jacques; Y Zheng; J Gordon; K Khalili; N L Letvin; I J Koralnik
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 10.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.